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Abstract Cloning natural product biosynthetic gene
clusters from cultured or uncultured sources and their
subsequent expression by genetically tractable heterol-
ogous hosts is an essential strategy for the elucidation
and characterisation of novel microbial natural prod-
ucts. The availability of suitable expression hosts is a
critical aspect of this workflow. In this work, we
mutagenised five endogenous biosynthetic gene clus-
ters from Streptomyces albus S4, which reduced the
complexity of chemical extracts generated from the
strain and eliminated antifungal and antibacterial
bioactivity. We showed that the resulting quintuple
mutant can express foreign biosynthetic gene clusters
by heterologously producing actinorhodin, cin-
namycin and prunustatin. We envisage that our strain
will be a useful addition to the growing suite of
heterologous expression hosts available for exploring
microbial secondary metabolism.
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Introduction
The majority of clinically used antibiotics are derived
from natural products produced by Streptomyces
species and other closely related Actinobacteria,
which were introduced into the clinic during a ‘golden
era’ of antibiotic discovery spanning 1940–1960 (Katz
and Baltz 2016). The utility of these agents has been
eroded over the last half-century due to misuse. As a
consequence, there is now an urgent need to discover
new antibiotics to treat bacterial infections, particu-
larly those caused by drug-resistant ‘ESKAPE’
pathogens (Enterococcus faecium, Staphylococcus
aureus, Klebsiella pneumoniae, Acinetobacter bau-
manii, Pseudomonas aeruginosa, and Enterobacter
species) (Boucher et al. 2009). Growing concerns
about resistance to antibacterial agents combined with
the failure to find new leads from the screening of large
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libraries of synthetic compounds has led to a renewed
interest in natural products discovery (Payne et al.
2006). This renaissance has been fuelled to a large
extent by the relatively inexpensive cost to sequence
genomes of strains that produce promising bioactive
small molecules. For example, there are cur-
rently[ 750 streptomycete genomes available in
GenBank compared to four years ago when there
were only * 150 (Seipke 2015). Analysis of these
genome sequences has illuminated the exciting
prospect that the majority of microbial secondary
metabolism has yet to be uncovered (Doroghazi et al.
2014).
Further study of potentially interesting natural
product biosynthetic pathways is often precluded by
the poor growth characteristics of the strain and/or
genetic intractability. Therefore, a heterologous
expression strategy using a faster-growing and genet-
ically tractable host is frequently adopted and indeed
has become the method of choice for accessing new
natural products and interrogating their biosynthesis.
Technology for generating and screening large-insert
genomic libraries (e.g. cosmid, BAC and PAC
libraries) to obtain biosynthetic gene cluster (BGC)
clones are well established (Jones et al. 2013; Qin et al.
2017). These approaches are in the process of being
superseded by recombination-based cloning methods
for targeted ‘capture’ of DNA both from isogenic
strains (Yamanaka et al. 2014) and environmental
DNA (Hover et al. 2018) as well as the ability to
assemble natural/synthetic DNA in vivo and in vitro
(recently reviewed by (Kim et al. 2015; Luo et al.
2016; Zhang et al. 2016)).
Although fastidiously growing bacterial species,
such as Escherichia coli, have been used for some
heterologous expression studies, its use has thus far
been rather limited because of poor expression of
native promoter systems, but in some cases can be
overcome by engineered promoter swaps either with
the T7 promoter or those recognised by alternative
RNA polymerase sigma factors (Stevens et al. 2013;
Liu et al. 2015). As a consequence, streptomycetes and
other related genera such as Saccharopolyspora and
Salinispora are the go-to platform for heterologous
expression, because they are metabolically robust with
respect to availability of precursors and cofactors, and
native promoter elements are more likely to be
functional compared to alternative hosts (Zhang
et al. 2016; Schniete et al. 2018). Unsurprisingly, well
studied species of Streptomyces such as S. avermitilis,
S. coelicolor, S. lividans and S. venezuelae are
commonly used for heterologous expression studies
(Huo et al. 2019; Nepal and Wang 2019). Several of
the aforementioned species have been engineered for
improved heterologous expression, principally via the
mutation of endogenous BGCs (Komatsu et al.
2010, 2013; Gomez-Escribano and Bibb 2011;
Thanapipatsiri et al. 2015).
Despite the utility of these strains, S. albus is still
frequently used as a heterologous expression host. S.
albus strains are seemingly distributed worldwide and
encode a diverse range of natural products produced
by a variety of biosynthetic systems (Seipke 2015;
Joynt and Seipke 2018). They are genetically
tractable and grow relatively quickly using conven-
tional growth media and methodology. S. albus J1074
in particular has served as a workhorse for heterolo-
gous production of natural products over the last two
decades. Recently, a strain of S. albus J1074 was
generated that harbours deletions in 15 of its 22
putative BGCs (Myronovskyi et al. 2018). The
resulting strain, which was named Del14, is deficient
in the production of several known compounds (i.e.
frontalamide, paulomycin, indigoidine, carotenoids,
flaviolin, candicidin and antimycin) as well as com-
pounds yet to be characterised (Myronovskyi et al.
2018). Relatively recently, we isolated a strepto-
mycete from leafcutting ants that is closely related to
S. albus J1074, which we designated Streptomyces
albus S4 (Barke et al. 2010). J1074 and S4 are
phylogenetically closely related strains differing in
only 12 nucleotide positions across[ 12 kb of DNA
sequence representing 29 conserved single-copy con-
served phylogenetic markers (Joynt and Seipke 2018).
The two strains share * 80% of their BGCs, but S4
encodes a larger and more diverse complement of
secondary metabolites (Seipke 2015). The genetic
tractability, robust and fastidious growth and ability to
produce diverse secondary metabolites motivated us
to modify this strain for easier detection of heterolo-
gously produced natural products.
There were two major aims of this work, the first
aim was to construct a strain that when cultivated
under routine conditions was unable to produce
antifungal or antibacterial compounds, and the second
aim was to construct a strain from which chemical
extracts with reduced complexity could be generated.
Here we describe the construction of a chromatogram-
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simplified strain of S. albus S4 where five BGCs have
been mutated and we demonstrate its ability to
heterologously produce actinorhodin, cinnamycin
and prunustatin.
Materials and methods
Growth media, strains and reagents
Escherichia coli strains were cultivated using Lennox
agar (LA) or broth (LB) and Streptomyces strains were
cultured using mannitol-soya flour (MS) agar, tryptic
soy broth (TSB) or agar (TSA) (Kieser et al. 2002).
Culture media was supplemented with antibiotics as
required at the following concentrations: apramycin
(50 lg/ml), carbenicillin (100 lg/ml), hygromycin
(75 lg/ml), kanamycin (50 lg/ml), nalidixic acid
(25 lg/ml). Enzymes were purchased from New
England Biolabs and oligonucleotides were purchased
from Integrated DNA Technologies. The bacterial
strains, cosmids and plasmids used in this study are
described in Table S1 and the oligonucleotides are
described in Table S2.
Mutagenesis of biosynthetic gene clusters
In order to delete the ant BGC, the antF gene on S4
Cosmid213 (Seipke et al. 2014) was replaced with the
apramycin resistance cassette from pIJ773 using PCR
targeted mutagenesis as previously described (Gust
et al. 2003). The mutated cosmid was used to generate
an apramycin resistant S. albus S4 DantF strain. Next,
antABCDEFGHIJKLMNO on Cosmid213 were
replaced with the apramycin resistance cassette in
the same manner as above and subsequently removed
by the Flp recombinase, after which the bla gene was
replaced with the hygromycin resistance cassette also
harbouring an oriT from pIJ10701 as previously
described (Gust et al. 2003) to result in Cosmid213
DantFLP B2H. This cosmid was mobilised to S. albus
S4 DantF and a single hygromycin resistant transcon-
jugant was selected and subsequently passaged twice
in the absence of selection prior to replica plate
identification of an apramycin sensitive and hygro-
mycin sensitive isolate that we named S. albus S4 D1.
The integrity of this strain was confirmed by PCR
using primers RFS236 and RFS237.
The can BGC was mutated using the previously
constructed fscC (STRS4_02234) deletion plasmid,
pKC1132-UpDn (Seipke et al. 2011a). pKC1132-
UpDn was mobilised to S. albus S4 D1 strain and a
single apramycin resistant transconjugant was selected
and passaged as above until an apramycin-sensitive
isolate was identified, which we named S. albus S4D2.
The surugamide, fredericamycin and albaflavenone
BGCs were mutated using the pCRISPomyces-2
system describe previously (Cobb et al. 2015). First,
a single-guide RNA protospacer was generated by
annealing oligonucleotides EH_S9 and EH_S10 (su-
rugamide), EH_S3 and EH_S4 (albaflavenone) and
EH_S7 and EH_S8 (fredericamycin); the resulting
DNA fragments were cloned into the BbsI site of
pCRISPomyces-2 by Golden Gate Assembly. Second,
two overlapping DNA fragments representing a
homology-directed repair template were generated
by PCR using the primers listed in Table S2. The
overlapping PCR products were subsequently cloned
into the XbaI site of protospacer-containing pCRIS-
Pomyces-2 plasmid using the NEBbuilder HiFi DNA
assembly kit. The resulting CRISPR/Cas9 editing
plasmids, pCRISPomyces-2-sur, pCRISPomyces-2-
alb, pCRISPomyces-2-fdm were sequentially mobi-
lised to Streptomyces and cured as described previ-
ously (McLean et al. 2016) and schematically
illustrated in Figure S1 to result in the quintuple
mutant strain described in this study, S. albus S4 D5.
Genome sequencing and bioinformatics analysis
S. albus S4 D5 chromosomal DNA was sequenced by
Microbes NG (Birmingham, UK) using the Illumina
MiSeq platform. This resulted in the generation of
2,859,380 paired-end reads that were 250 nt in length.
2,809,652 of these reads were mapped the S. albus S4
wild-type chromosome [GenBank accession
CADY00000000.1 (Seipke et al. 2011b)] using the
Geneious assembler (version R8.1.19). Schematic
representations of relevant loci depicted in Figs. S2-
S6 were generated using Geneious version R8.1.19.
Bioactivity assays
Indicator organism was cultivated overnight in LB at
37 C. Overnight culture was diluted to an OD625nm of
0.08 in LB and spread onto an LB agar plate using a
rotary platform. Sterile paper discs (6 mm diameter)
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holding 60 ll of chemical extract were placed atop
seeded indicator plates, which were subsequently
incubated at 37 C (Micrococcus luteus) or room
temperature (Candida albicans) and visualized the
following day.
HPLC analysis
S. albus strains were cultivated in liquid MS (50 ml)
whilst shaking at 220 rpm in a 250 ml flask at 30 C
for 7 days. Bacterial cells and solid matter from the
culture medium were removed by centrifugation and
45 ml of supernatant were extracted with 90 ml of
ethyl acetate. The extract was evaporated to dryness
under reduced pressure and resuspended in 100%
methanol (500 ll). The methanolic extract was cen-
trifuged for 10 min at 16,000 9 g to remove insoluble
material prior to sample injection (10 ll) into a
Dionex HPLC instrument. Compounds were separated
on a Phenomenex Luna C18 column (5 lm,
150 9 4.6 mm) using the following gradient (solvent
A: 5% acetonitrile, 0.1% formic acid, solvent B: 95%
acetonitrile, 0.05% formic acid, flow rate 1 ml/min):
0–40 min, 0–100% B; 40–43 min, 100% B;
43–51 min 0% B.
LCMS analysis
Clones of the actinorhodin, cinnamycin and neoan-
timycin BGCs were introduced into S. albus D5 by
intergeneric conjugation from Escherichia coli
ET12567/pUZ8002. Apramycin resistant transconju-
gants were verified to have received BGCs by PCR.
For the production of actinorhodin and prunustatin,
MS agar plates (pH 6.7) were seeded with either D5 or
D5/Act or D5/Prun and cultivated for 7 days at 30 C.
The agar was then cut into small rectangular pieces
and placed into an Erlenmeyer flask and metabolites
extracted with ethyl acetate (100 ml) for 24 h. The
ethyl acetate extract was decanted and concentrated in
vacuo and the dried residue was resuspended in 100%
methanol (500 ll). For the production of cinnamycin,
S. albus S4 D5 and D5/Cin strains were cultured in
50 ml TSB (pH 7.0) for 7 days at 30 C. The resulting
mycelia was collected by centrifugation and extracted
with 100% methanol (45 ml) for 4 h. The methanolic
extracts were evaporated to dryness in vacuo and
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cosmid213∆antF,
cosmid213∆antF-FLP-B2H pKC1132-UpDN pCRISPomyces-2-sur pCRISPomyces-2-alb pCRISPomyces-2-fdm
S. albus S4 WT S. albus S4 ∆3 S. albus S4 ∆4 S. albus S4 ∆5
B
Antimycin Candicidin AlbaﬂavenoneSurugamide Fredericamycin
Fig. 1 Streptomyces albus S4 biosynthetic gene clusters
(BGCs) and their mutation. a Diagrammatic representation of
putative BGCs identified by antiSMASH 3.0. The BGCs are
numbered and the experimentally determined or bioinformati-
cally deduced products are listed where known. BGCs targeted
for mutagenesis in this study are indicated by bold text.
b Schematic of the workflow used to create S. albus S4 D5.
Knockout constructs are colour coded according to their
targeted mutation and plasmid and strain designations are
described in Table S1. The bottom panel depicts IlluminaMiSeq
reads mapped to the relevant locus of the S. albus S4 D5 genome
illustrating that the desired mutation was achieved. The scissors
indicate cleavage by the Cas9 nuclease. Full size versions of
these images are shown in Figures S1-S5. (Color figure online)
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resuspended in 100% methanol (500 ll) as above.
Equal volumes of methanolic extract for three inde-
pendently cultivated replicates of D5, D5/Act, D5/Cin,
D5/Prun were pooled and centrifuged for 10 min at
16,000 9 g to remove insoluble material prior to
analysis by high resolution electrospray ionization
liquid chromatography mass spectrometry (LC-
HRMS). Only the supernatant (2 ll) was injected into
a Bruker MaXis Impact TOF mass spectrometer and
equipped with a Dionex Ultimate 3000 HPLC exactly
as previously described (Liu et al. 2015).
Results and Discussion
Construction of Streptomyces albus S4 D5
The S. albus S4 genome was previously sequenced
(Seipke et al. 2011a, b) and it harbours at least 28
putative natural product biosynthetic gene clusters
(BGCs) according to antiSMASH 3.0 (Fig. 1a) (We-
ber et al. 2015). Chemical extracts prepared from S.
albus S4 cultivated under a variety of culture condi-
tions are dominated by antimycins and candicidin
(Barke et al. 2010; Seipke et al. 2011a). Therefore,
abolishing production of these compounds was a top
priority in our mutagenesis strategy. With the longer-
term goal of ultimately developing an S. albus host as a
platform to screen uncharacterised BGC clones for
WT
Δ5
A B
C
WT Δ5
D
0.0
0.5
1.0
1.5
2.0
w
et
 m
yc
el
ia
l m
as
s 
(g
)
1
2
3 4
5
61
2
3
4
5
6
Fig. 2 S. albus S4 D5 sporulates normally and produces
biomass equal to that of the WT strain during growth in liquid
media. a Sporulation of S. albus strains after growth on MS agar
for 7 days. b Wet cell mass of S. albus strains originating from
TSB cultures. The values reported are the means for a 20 ml
sample of culture and the vertical bars represent the standard
error of the mean (n = 3). The results are not statistically
significantly different in a Student’s t test with a P value[ 0.60.
Bioactivity of ethyl acetate chemical extracts generated from S.
albus strains cultivated in liquid MS against c Candida albicans
and dMicrococcus luteus. The discs on each plate are numbered
and are as follows: 1, methanol; 2, extract fromMSmedia; 3 and
4, S. albusD5 extract; 5 and 6, S. albus S4WT extract. A zone of
inhibited growth is apparent only for the wild-type extract
against C. albicans
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antibacterial activity, we also targeted the albaflave-
none, surugamide and fredericamycin BGCs because
these compounds have been reported to have antibac-
terial properties (Warnick-Pickle et al. 1981; Gu¨rtler
et al. 1994; Wang et al. 2014). We mutated these five
BGCs using conventional marker exchange mutage-
nesis (candicidin), PCR-targeted recombineering (an-
timycin) and CRISPR/Cas9 genome editing
(albaflavenone, surugamide and fredericamycin).
The workflow for this strategy is presented in Fig. 1b
and is described in the materials and methods
section. The final mutant strain, which we designated
S. albus S4 D5, harbours a complete pathway deletion
in the antimycin BGC, and deletions in key biosyn-
thetic genes for the other four targeted BGCs.
Deletions were first verified by PCR and the overall
integrity of the S. albus S4 D5 strain was verified by
genome sequencing using the Illumina MiSeq plat-
form. The expected mutations were verified by
mapping sequence reads to the S. albus S4 wild-type
genome sequence (Seipke et al. 2011b). A schematic
representation of the relevant areas of the mapping are
displayed in Fig. 1b and Figs. S1-S5.
Sporulation, biomass and bioactivity of D5
In order to ensure that serial passage (e.g. to cure
plasmids with temperature-sensitive replicons such as
that employed by pCRISPomyces-2) did not lead to
mutation(s) adversely impacting sporulation and/or
growth of D5, we assessed sporulation onMS agar and
analysed its ability to produce biomass when culti-
vated using TSB. The D5 mutant strain sporulated
equally as well as the wild-type strain, which indicated
the absence of mutations deleterious to a normal
developmental cycle and it also produced a compara-
ble abundance of dispersed biomass to that of its
parent (Fig. 2a, b). Next, we analysed the bioactivity of
ethyl acetate chemical extracts prepared from culture
supernatants of S. albus S4 wild-type or D5 cultivated
in liquid MS against Candida albicans andMicrococ-
cus luteus, which revealed that extracts from the D5
strain were not bioactive (Fig. 2c, d).
Chromatographic profile of D5
Chemical extracts generated from S. albus S4 wild-
type are complex and chromatographs are dominated
by candicidins and antimycins when using a standard
aqueous/organic phase gradient of 5–95% acetonitrile
or methanol (Seipke et al. 2011a, 2014). In order to
assess to what extent this complexity was reduced in
extracts generated from the D5 mutant, we cultivated
S4 wild-type and D5 using liquid MS and performed
an ethyl acetate extraction of the resulting clarified
culture supernatant. Next, extracts were analysed by
HPLC, which as anticipated, revealed that the extracts
generated from the D5 were far less complex than
those generated from the wild-type strain (Fig. 3). The
cleaner chromatographic background of the S. albus
S4 D5 strain will simplify detection of heterologously
produced natural products by HPLC or LC–MS and
ease their subsequent purification.
Heterologous production of actinorhodin,
cinnamycin and prunustatin
As a proof of principle to demonstrate that S4 D5 can
produce natural products encoded by other taxa, we
introduced three foreign BGCs: the actinorhodin BGC
from S. coelicolorA3(2), the cinnamycin BGC from S.
cinnamoneus DSM 40,646 and the neoantimycin/
Fig. 3 HPLC analysis of ethyl acetate extracts prepared from S.
albus S4 WT and D5 strains. The HPLC chromatogram
originating from the D5 strain is simpler in composition
compared to that of the WT strain. The asterisks indicate HPLC
peaks that are not fully visible in this image, but can be seen in
Fig. S6
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prunustatin BGC from S. orinoci B-NRRL 3379
(Widdick et al. 2003; Gomez-Escribano and Bibb
2011; Skyrud et al. 2018). These BGCs were selected
in part due to accessibility, but also because they
comprised three different biosynthetic systems. Acti-
norhodin is a type II polyketide antibacterial, cin-
namycin is a ribosomally synthesised and post-
translationally modified peptide antibacterial and
neoantimycin/prunustatin is a hybrid non-ribosomal
peptide / polyketide anti-cancer compound. Recom-
binant strains harbouring these BGCs were generated
and cultivated using MS agar or TSB for seven days.
Next, chemical extracts were prepared from the D5/
Act, D5/Cin, D5/Prun strains and their parent and
subsequently analysed by LC-HRMS (Fig. 4). Inspec-
tion of the resulting data revealed the presence of
compounds consistent with c-actinorhodin, cin-
namycin and prunustatin in chemical extracts prepared
from D5/Act, D5/Cin, D5/Prun, respectively and
importantly, their absence from the D5 parental strain.
These data indicate that S. albus S4 D5 is capable of
heterologous expressing foreign BGCs from classes of
varying biosynthetic logic.
Summary and concluding perspectives
We have constructed a strain of S. albus S4 in which
the antimycin, candicidin, albaflavenone, surugamide
and fredericamycin BGCs have been mutated. We
showed that the resulting strain, S. albus S4 D5,
possessed a simpler chromatographic profile and did
not possess antibacterial or antifungal activity using
the growth media tested and also demonstrated that it
could serve as a surrogate host for the production of
actinorhodin, cinnamycin and prunustatin.
Fig. 4 Heterologous
production of c-
actinorhodin (1),
cinnamycin (2) and
prunustatin (3) by S. albus
S4 D5. LC-HRMS analysis
of chemical extracts
prepared from the indicated
strains. The m/z values
corresponding to the
[M ? 2H]2?ions derived
from c-actinorhodin
(C32H22O14), cinnamycin
(C89H125N25O25S3), and
prunustatin (C36H44N2O12)
are shown. The intensity
scale for extracted ion
chromatograms is 1 9 104
for c-actinorhodin and
cinnamycin, and 1 9 105
for prunustatin
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Interestingly, during the course of our study we also
tried to heterologously produce bicyclomycin and
methylenomycin, but were unable to detect either
metabolite by LC-HRMS. The unsuccessful attempt to
heterologously produce bicyclomycin and methyleno-
mycin underscores a key consideration for heterolo-
gous expression studies – host selection. For instance,
S. coelicolor is a native producer of methylenomycin
and was recently used as a host for bicyclomycin
production (Vior et al. 2018), however it will not
produce neoantimycin/prunustatin unless the biosyn-
thetic genes are artificially expressed from constitutive
promoters (Skyrud et al. 2018). Indeed, there is no
panacea in terms of a heterologous expression host,
each one being somewhat enigmatic with peculiarities
rooted in primary metabolism (i.e. precursor and co-
factor supply) or promoter recognition elements.
Fortuitously, there are now greater flexibility than
ever before in terms of host selection. For instance, a
suite of S. coelicolor M145 DactDredDcdaDcpk
variants (M1146, M1152, M1154) are a commonly
used (Gomez-Escribano and Bibb 2011). Addition-
ally, the endogenous BGC content of S. avermitilis
was also reduced to enhance production and detection
of heterologous compounds (Komatsu et al.
2010, 2013) and an impressive 15 BGCs were recently
removed from S. albus J1074.
(Myronovskyi et al. 2018). It is therefore possible,
and indeed advantageous and wise when pursuing
heterologous expression of a BGC to cast a wide net
and screen multiple hosts. The S. albus S4 D5 strain
constructed here will hopefully be a useful tool to that
end.
Acknowledgements We are grateful to Iain Manfield for
assistance with HPLC experiments, which were conducted in
the University of Leeds Biomolecular Interactions Facility. We
thank David Widdick and Mervyn Bibb for providing the
cinnamycin and actinorhodin BGC clones, Andy Truman for
providing the bicyclomycin BGC clone and Christophe Corre
for providing the methylenomycin BGC clone. This work was
supported by Biotechnology and Biological Sciences Research
Council responsive mode Grant BB/N007980/1 awarded to
RFS. AF and DT were funded by PhD studentships funded by
the University of Leeds.
Compliance with ethical standards
Conflict of interest The authors declare that there are no
conflicts of interest and that the funders had no role in study
design, data collection and interpretation, or the decision to
submit the work for publication.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unre-
stricted use, distribution, and reproduction in any medium,
provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative Com-
mons license, and indicate if changes were made.
References
Barke J, Seipke RF, Gru¨schow S, Heavens D, Drou N, Bibb MJ,
Goss RJM, Yu DW, Hutchings MI (2010) A mixed com-
munity of actinomycetes produce multiple antibiotics for
the fungus farming ant Acromyrmex octospinosus. BMC
Biol 8:109. https://doi.org/10.1186/1741-7007-8-109
Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D,
Rice LB, Scheld M, Spellberg B, Bartlett J (2009) Bad
bugs, no drugs: no ESKAPE! An update from the Infec-
tious Diseases Society of America. Clin Infecti Dis
48:1–12. https://doi.org/10.1086/595011
Cobb RE, Wang Y, Zhao H (2015) High-efficiency multiplex
genome editing of Streptomyces species using an engi-
neered CRISPR/Cas system. ACS Synth Biol 4:723–728.
https://doi.org/10.1021/sb500351f
Doroghazi JR, Albright JC, Goering AW, Haines RR, Tchalu-
kov KA, Labeda DP, Metcalf WW (2014) A roadmap for
natural product discovery based on large-scale genomics
and metabolomics. Nat Chem Biol 10:963–968. https://doi.
org/10.1038/nchembio.1659
Gomez-Escribano JP, Bibb MJ (2011) Engineering Strepto-
myces coelicolor for heterologous expression of secondary
metabolite gene clusters. Microbial Biotechnol 4:207–215.
https://doi.org/10.1111/j.1751-7915.2010.00219.x
Gu¨rtler H, Pedersen R, Anthoni U, Christophersen C, Nielsen
PH, Wellington EM, Pedersen C, Bock K (1994) Alba-
flavenone, a sesquiterpene ketone with a zizaene skeleton
produced by a streptomycete with a new rope morphology.
J Antibiot 47:434–439
Gust B, Challis GL, Fowler K, Kieser T, Chater KF (2003) PCR-
targeted Streptomyces gene replacement identifies a pro-
tein domain needed for biosynthesis of the sesquiterpene
soil odor geosmin. Proc Natl Acad Sci USA
100:1541–1546. https://doi.org/10.1073/pnas.0337542100
Hover BM, Kim S-H, Katz M, Charlop-Powers Z, Owen JG,
Ternei MA,Maniko J, Estrela AB,Molina H, Park S, Perlin
DS, Brady SF (2018) Culture-independent discovery of the
malacidins as calcium-dependent antibiotics with activity
against multidrug-resistant Gram-positive pathogens. Nat
Microbiol 3:1–10. https://doi.org/10.1038/s41564-018-
0110-1
Huo L, Hug JJ, Fu C, Bian X, Zhang Y, Mu¨ller R (2019)
Heterologous expression of bacterial natural product
biosynthetic pathways. Nat Prod Rep 4:206–225. https://
doi.org/10.1039/C8NP00091C
Jones AC, Gust B, Kulik A, Heide L, Buttner MJ, Bibb MJ
(2013) Phage P1-Derived Artificial chromosomes facilitate
heterologous expression of the FK506 gene cluster. PLoS
123
Antonie van Leeuwenhoek
ONE 8:e69319–e69329. https://doi.org/10.1371/journal.
pone.0069319
Joynt R, Seipke RF (2018) A phylogenetic and evolutionary
analysis of antimycin biosynthesis. Microbiology
164:28–39. https://doi.org/10.1099/mic.0.000572
Katz L, Baltz RH (2016) Natural product discovery: past, pre-
sent, and future. J Indian Microbiol Biotechnol
43:155–176. https://doi.org/10.1007/s10295-015-1723-5
Kieser TB, Buttner MJ, Chater KF, Hopwood DA (2002)
Practical Streptomyces genetics. The John Innes Founda-
tion, Norwich
Kim E, Moore BS, Yoon YJ (2015) Reinvigorating natural
product combinatorial biosynthesis with synthetic biology.
Nat Chem Biol 11:649–659. https://doi.org/10.1038/
nchembio.1893
Komatsu M, Uchiyama T, Omura S, Cane DE, Ikeda H (2010)
Genome-minimized Streptomyces host for the heterolo-
gous expression of secondary metabolism. Proc Natl Acad
Sci USA 107:2646–2651. https://doi.org/10.1073/pnas.
0914833107
Komatsu M, Komatsu K, Koiwai H, Yamada Y, Kozone I,
Izumikawa M, Hashimoto J, Takagi M, Omura S, Shin-ya
K, Cane DE, Ikeda H (2013) Engineered Streptomyces
avermitilis host for heterologous expression of biosynthetic
gene cluster for secondary metabolites. ACS Synth Biol
2:384–396. https://doi.org/10.1021/sb3001003
Liu J, Zhu X, Seipke RF, Zhang W (2015) Biosynthesis of
antimycins with a reconstituted 3-formamidosalicylate
pharmacophore in Escherichia coli. ACS Synth Biol
4:559–565. https://doi.org/10.1021/sb5003136
Luo Y, Enghiad B, Zhao H (2016) New tools for reconstruction
and heterologous expression of natural product biosyn-
thetic gene clusters. Nat Prod Rep 33:174–182. https://doi.
org/10.1039/C5NP00085H
McLean TC, Hoskisson PA, Seipke RF (2016) Coordinate
regulation of antimycin and candicidin biosynthesis.
mSphere 1:e00305–16. https://doi.org/10.1128/mSphere.
00305-16
Myronovskyi M, Rosenkra¨nzer B, Nadmid S, Pujic P, Normand
P, Luzhetskyy A (2018) Generation of a cluster-free
Streptomyces albus chassis strains for improved heterolo-
gous expression of secondary metabolite clusters. Metab
Eng 49:316–324. https://doi.org/10.1016/j.ymben.2018.
09.004
Nepal KK, Wang G (2019) Streptomycetes_ Surrogate hosts for
the genetic manipulation of biosynthetic gene clusters and
production of natural products. Biotechnol Adv 37:1–20.
https://doi.org/10.1016/j.biotechadv.2018.10.003
Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL (2006)
Drugs for bad bugs: confronting the challenges of
antibacterial discovery. Nat Rev Drug Discov 6:29–40.
https://doi.org/10.1038/nrd2201
Qin Z, Munnoch JT, Devine R, Holmes NA, Seipke RF,
Wilkinson KA, Wilkinson B, Hutchings MI (2017)
Formicamycins, antibacterial polyketides produced by
Streptomyces formicae isolated from African Tetraponera
plant-ants. Chem Sci 8:3218–3227. https://doi.org/10.
1039/c6sc04265a
Schniete JK, Cruz-Morales P, Selem Mojica N, Ferna´ndez-
Martı´nez LT, Hunter IS, Barona-Go´mez F, Hoskisson PA
(2018) Expanding primary metabolism helps generate the
metabolic robustness to facilitate antibiotic biosynthesis in
Streptomyces. mBio 9:e02283–17–13. https://doi.org/10.
1128/mBio.02283-17
Seipke RF (2015) Strain-level diversity of secondary metabo-
lism in Streptomyces albus. PLoS ONE 10:e0116457–
e116514. https://doi.org/10.1371/journal.pone.0116457
Seipke RF, Barke J, Brearley C, Hill L, Yu DW, Goss RJM,
Hutchings MI (2011a) A Single Streptomyces symbiont
makes multiple antifungals to support the fungus farming
ant Acromyrmex octospinosus. PLoS ONE 6:e22028–
e22038. https://doi.org/10.1371/journal.pone.0022028
Seipke RF, Crossman L, Drou N, Heavens D, Bibb MJ, Cac-
camo M, Hutchings MI (2011b) Draft genome sequence of
Streptomyces strain S4, a symbiont of the leaf-cutting ant
Acromyrmex octospinosus. J Bacteriol 193:4270–4271.
https://doi.org/10.1128/JB.05275-11
Seipke RF, Patrick E, Hutchings MI (2014) Regulation of
antimycin biosynthesis by the orphan ECF RNA poly-
merase sigma factor rAntA. PeerJ 2:e253. https://doi.org/
10.7717/peerj.253
Skyrud W, Liu J, Thankachan D, Cabrera M, Seipke RF, Zhang
W (2018) Biosynthesis of the 15-membered ring dep-
sipeptide neoantimycin. ACS Chem Biol 13:1398–1406.
https://doi.org/10.1021/acschembio.8b00298
Stevens DC, Conway KR, Pearce N, Villegas-Pen˜aranda LR,
Garza AG, Boddy CN (2013) Alternative sigma factor
over-expression enables heterologous expression of a type
II polyketide biosynthetic pathway in Escherichia coli.
PLoS ONE 8:e64858. https://doi.org/10.1371/journal.
pone.0064858
Thanapipatsiri A, Claesen J, Gomez-Escribano JP, Bibb M,
Thamchaipenet A (2015) A Streptomyces coelicolor host
for the heterologous expression of Type III polyketide
synthase genes. Microb Cell Fact 14:1–11. https://doi.org/
10.1186/s12934-015-0335-0
Vior NM, Lacret R, Chandra G, Dorai-Raj S, Trick M, Truman
AW (2018) Discovery and biosynthesis of the antibiotic
bicyclomycin in distantly related bacterial classes. Appl
Environ Microbiol 84:e02828–e2917. https://doi.org/10.
1128/AEM.02828-17
Wang X, Shaaban KA, Elshahawi SI, Ponomareva LV, Sunkara
M, Copley GC, Hower JC, Morris AJ, Kharel MK, Thorson
JS (2014) Mullinamides A and B, new cyclopeptides pro-
duced by the Ruth Mullins coal mine fire isolate Strepto-
myces sp. RM-27-46. J Antibiot 67:571–575. https://doi.
org/10.1038/ja.2014.37
Warnick-Pickle DJ, Byrne KM, Pandey RC, White RJ (1981)
Fredericamycin A, a new antitumor antibiotic. II. Biolog-
ical properties. J Antibiot 34:1402–1407
Weber T, Blin K, Duddela S, Krug D, Kim HU, Bruccoleri R,
Lee SY, Fischbach MA, Mu¨ller R, WohllebenW, Breitling
R, Takano E, Medema MH (2015) antiSMASH 3.0—a
comprehensive resource for the genome mining of
biosynthetic gene clusters. Nucleic Acids Res 43:W237–
W243. https://doi.org/10.1093/nar/gkv437
Widdick DA, Dodd HM, Barraille P, White J, Stein TH, Chater
KF, Gasson MJ, Bibb MJ (2003) Cloning and engineering
of the cinnamycin biosynthetic gene cluster from Strepto-
myces cinnamoneus cinnamoneus DSM 40005. Proc Natl
Acad Sci USA 100:4316–4321. https://doi.org/10.1073/
pnas.0230516100
123
Antonie van Leeuwenhoek
Yamanaka K, Reynolds KA, Kersten RD, Ryan KS, Gonzalez
DJ, Nizet V, Dorrestein PC, Moore BS (2014) Direct
cloning and refactoring of a silent lipopeptide biosynthetic
gene cluster yields the antibiotic taromycin A. Proc Natl
Acad Sci USA 111:1957–1962. https://doi.org/10.1073/
pnas.1319584111
Zhang MM, Wang Y, Ang EL, Zhao H (2016) Engineering
microbial hosts for production of bacterial natural
products. Nat Prod Rep 00:1–25. https://doi.org/10.1039/
C6NP00017G
Publisher’s Note Springer Nature remains neutral with
regard to jurisdictional claims in published maps and
institutional affiliations.
123
Antonie van Leeuwenhoek
